Luigi Lenaz - Spectrum Pharmaceuticals Director
| SPPIDelisted Stock | USD 1.03 0.00 0.00% |
Director
Dr. Luigi Lenaz, M.D., is a Lead Independent Director of the Company. Dr. Lenaz was unanimously elected as Lead Director by the independent directors of the Board on October 14, 2016 and has served as a director of Spectrum since June 2010. From 1978 to 1997, Dr. Lenaz held several senior management positions with BristolMyers Squibb Company, a NYSElisted pharmaceutical company, including Senior Vice President of Oncology Franchise Management from 1990 to 1997 and Director of Scientific Affairs, AntiCancer from 1985 to 1990. From 1997 to 2000, Dr. Lenaz served as Senior Vice President of Clinical Research, Medical Affairs at SuperGen, Inc., a NASDAQlisted pharmaceutical company dedicated to cancer drug development. Dr. Lenaz served as President of Spectrums Oncology Division from 2000 to 2005 and as Spectrums Chief Scientific Officer from February 2005 to June 2008. Dr. Lenaz is also a prominent researcher, having conducted research in the areas of pharmacology, experimental chemotherapy, histology, general physiology, and experimental therapeutics at various institutions for cancer research, including Roswell Park Memorial Institute, Memorial SloanKettering Cancer Center and the National Cancer Institute in Milan. He is a member of several scientific societies, including the American Association for Cancer Research, American Association for Clinical Oncology, European Society for Medical Oncology, and International Association for the Study of Lung Cancer. Dr. Lenaz served as a director of PharmacoKinesis Corporationrationration, a privatelyheld medical device company, from 2009 to 2014. Dr. Lenaz is a graduate of Liceo Scientifico A. Righi in Bologna, Italy and he received a medical degree from the University of Bologna Medical School in 1966. since 2016.
| Age | 75 |
| Tenure | 8 years |
| Phone | 617 586 3900 |
| Web | https://www.sppirx.com |
Spectrum Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3821) % which means that it has lost $0.3821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6502) %, meaning that it created substantial loss on money invested by shareholders. Spectrum Pharmaceuticals' management efficiency ratios could be used to measure how well Spectrum Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 29.43 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Spectrum Pharmaceuticals has a current ratio of 1.75, which is within standard range for the sector. Debt can assist Spectrum Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Spectrum Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Spectrum Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Spectrum to invest in growth at high rates of return. When we think about Spectrum Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Dawn Bir | Geron | 47 | |
| Marc TessierLavigne | Agios Pharm | 55 | |
| Pete Meyers | Immutep Ltd ADR | 46 | |
| William Bertrand | Ardelyx | 52 | |
| Deepika Pakianathan | Karyopharm Therapeutics | 53 | |
| Gordon Ringold | Ardelyx | 66 | |
| Dennis Ausiello | Seres Therapeutics | 72 | |
| Alison Lawton | Verastem | 56 | |
| Thomas Adams | Hepion Pharmaceuticals | 74 | |
| Paul Friedman | Verastem | 72 | |
| Doug Cole | Agios Pharm | 54 | |
| Jane Wasman | Rigel Pharmaceuticals | 61 | |
| Raphael Hofstein | BioLineRx | 67 | |
| Peter Ringrose | Rigel Pharmaceuticals | 72 | |
| Douglas Melton | Bluebird bio | 64 | |
| Stephen Sherwin | Rigel Pharmaceuticals | 66 | |
| Samuel Barker | Lexicon Pharmaceuticals | 75 | |
| Deepa Pakianathan | Karyopharm Therapeutics | 51 | |
| Brian Austad | Karyopharm Therapeutics | N/A | |
| Brian Kotzin | Rigel Pharmaceuticals | 69 | |
| Werner Cautreels | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.65 | |||
| Return On Asset | -0.38 |
Spectrum Pharmaceuticals Leadership Team
Elected by the shareholders, the Spectrum Pharmaceuticals' board of directors comprises two types of representatives: Spectrum Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectrum. The board's role is to monitor Spectrum Pharmaceuticals' management team and ensure that shareholders' interests are well served. Spectrum Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectrum Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stuart Krassner, Independent Director | ||
| Raymond Cohen, Independent Director | ||
| Michael Grabow, Exec Officer | ||
| Nora Brennan, Ex Officer | ||
| Joseph Turgeon, Pres and COO | ||
| Dolatrai Vyas, Independent Director | ||
| Keith McGahan, Senior Vice President Chief Legal Officer and Corporate Secretary | ||
| LLM JD, Chief VP | ||
| MD MBA, VP Devel | ||
| Jeffrey Vacirca, Director | ||
| William Ashton, Independent Director | ||
| Luigi Lenaz, Director | ||
| Gilles Gagnon, Director | ||
| Bimal Shah, VP Devel | ||
| Kurt Gustafson, CFO, Principal Accounting Officer and Executive VP | ||
| Rajesh Shrotriya, Chairman of the Board, CEO | ||
| Elizabeth Czerepak, Director | ||
| Bernice Welles, Independent Director | ||
| Thomas Riga, CEO Pres | ||
| Anthony Maida, Independent Director | ||
| MD FRCPC, Ex Officer |
Spectrum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spectrum Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.65 | |||
| Return On Asset | -0.38 | |||
| Profit Margin | (2.52) % | |||
| Operating Margin | (2.47) % | |||
| Current Valuation | 185.27 M | |||
| Shares Outstanding | 205.25 M | |||
| Shares Owned By Insiders | 11.00 % | |||
| Shares Owned By Institutions | 22.93 % | |||
| Number Of Shares Shorted | 3.33 M | |||
| Price To Earning | (19.44) X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Spectrum Stock
If you are still planning to invest in Spectrum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spectrum Pharmaceuticals' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |